The ripple effects of US cannabis rescheduling continue to dominate the global agenda today, with new data quantifying just how quickly operators are racing to align with federal Schedule III status. Pharmaceutical investors are circling cannabis-derivative drugmakers, the DEA is processing a flood of registration applications, and beyond Washington, regulators from Tel Aviv to Nassau are recalibrating their own frameworks for the post-reclassification era.
Cannabis Drugmakers Eye IPOs and Private Capital After US Reclassification
Reuters reports that companies developing cannabis-based pharmaceuticals are preparing public listings and chasing fresh private funding rounds, citing the federal move to Schedule III as the catalyst that finally opens the door to mainstream institutional capital. The shift removes long-standing banking and listing barriers that had kept Wall Street at arm’s length, signalling a potential reset for an investment thesis that has frustrated cannabis backers for the better part of a decade.
Source: Reuters
Nearly 400 Cannabis Businesses Rush to Register With the DEA
High Times reports that close to 400 cannabis operators have already filed DEA registration applications in the wake of Schedule III reclassification, opening a long-closed door to federally regulated activity. The surge underscores how quickly the sector is moving to operationalise its new status, but also raises immediate questions about DEA capacity, compliance costs, and how state-licensed operators will navigate dual oversight.
Source: High Times Magazine
National Survey Finds Cannabis Microdosing Outpaces Psychedelics in US
New research from UC San Diego shows microdosing of cannabis is now more prevalent among American adults than microdosing of psychedelics, reframing how regulators and clinicians should think about low-dose use patterns. The findings will sharpen the debate around product formulation, dosing guidance and labelling — particularly as a Schedule III environment opens the door to more rigorous clinical investigation of sub-perceptual cannabinoid use.
Source: UC San Diego Today
Israel Weighs Removing Smokeable Flower From Medical Cannabis Programme
MJBizDaily reports that Israeli regulators are openly debating whether smokeable flower should remain part of the country’s medical cannabis offering, with public health officials questioning the appropriateness of combustion-based delivery in a clinical context. The outcome would carry weight well beyond Israel: as one of the world’s most established medical cannabis markets, any move to restrict flower could influence pharmacy-led programmes from Germany to Australia.
Source: MJBizDaily
Bahamas Completes Cannabis Licensing Platform, Opening Caribbean Market
The chairman of the Bahamas Cannabis Authority has confirmed the country’s licensing platform for cannabis firms is complete and ready for applicants, paving the way for a regulated industry to take shape in the Caribbean. The move positions the Bahamas to compete with established cultivation jurisdictions and adds another small-state entrant to the global supply map at a moment when international medical demand is climbing.
Source: MMJDaily
Today’s stories trace a single connecting thread: the post-Schedule III industry is being built in real time, and the contours are emerging not just in Washington but in pharmacies, capital markets and regulators worldwide. Watch how quickly DEA application throughput catches up to demand — that bottleneck will set the tempo for the next investment cycle.
Stay up to date with all the latest on the Cannabis News Hub.
